Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
5
×
clinical trials
fda
5
×
life sciences
national blog main
boston blog main
eli lilly
indiana blog main
indiana top stories
san francisco blog main
san francisco top stories
amgen
boston top stories
europe blog main
europe top stories
national top stories
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
abaloparatide
aimmune therapeutics
allergy
alprazolam
anaphylaxis
andrew oxtoby
avapritinib
blueprint medicines
boehringer ingelheim
boston
boulder/denver blog main
boulder/denver top stories
cgrp inhibitors
chronic migraine
colucid pharmaceuticals
cstone pharmaceuticals
daniel edelman
deals
detroit blog main
detroit top stories
What
approval
5
×
drug
fda
developed
eli
friday
lilly
marketing
wins
won
acute
addresses
agency
aimmune
allergy
amgen
amgen’s
approved
awarded
bid
blueprint
boehringer
cancer
candidate
carries
causes
condition
currently
decades
diabetes
europe
european
expand
fallen
giant
giving
heart
immunotherapy
ingelheim
lasmiditan
Language
unset
5
×
Current search:
fda
×
biotech
×
approval
×
unset
×
@xconomy.com
3 years ago
Roche, Blueprint Medicines Team Up Again in $775M RET Cancer Drug Pact
@xconomy.com
4 years ago
FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes
@xconomy.com
4 years ago
Aimmune Awarded First FDA Approval for a Peanut Allergy Therapy
@xconomy.com
4 years ago
Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning
@xconomy.com
4 years ago
FDA OKs Lilly’s Lasmiditan, First New Acute Migraine Drug in Decades